Evidence map›Paper›PMID 41309289›Full record

ArticleDiabetes, obesity & metabolism2026

Cost-effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA

Guangxin Han, Xiaoning Zhang, Yubing Ye, Changsheng Wang, Li Hu, Hanbiao Wu, Zhikun Qiu, Fang Yuan, Jisheng Chen, Sha Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guangxin HanKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xiaoning ZhangDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yubing YeKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Changsheng WangKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Li HuDepartment of Endocrinology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Hanbiao WuKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Zhikun QiuKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Fang YuanSchool of Pharmacy, Clinical Pharmacy Department, Guangdong Pharmaceutical University, Guangzhou, China.
Jisheng ChenKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Sha LaiKey Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.ORCID 0009-0005-2214-5678

Funding

Health Economics Association of Guangdong Province 2025-WJMZ-66National Key Clinical Specialty Discipline Construction Program of China Z155080000004
6 · The paper itself

Abstract

objectiveTo evaluate the long-term cost-effectiveness of continuous glucose monitoring (CGM) versus self-monitoring of blood glucose (SMBG) in Chinese adults with uncontrolled type 2 diabetes (T2D) to inform optimal disease management and reimbursement policies.

methodsThe United Kingdom Prospective Diabetes Study Outcomes Model version 2 was used to simulate 30-year cost and health outcomes for cohorts with baseline HbA

resultsFor baseline HbA

conclusionsCGM represents a cost-effective intervention for Chinese adults with uncontrolled T2D, demonstrating enhanced economic value in populations with elevated baseline HbA

Indexed as

Blood Glucose Self-MonitoringDiabetes Mellitus, Type 2Glycated HemoglobinGlycemic ControlAdultAgedBlood GlucoseChinaContinuous Glucose MonitoringCost-Benefit AnalysisEast Asian PeopleFemaleHumansMaleMiddle AgedModels, EconomicBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humancontinuous glucose monitoringcost‐effectivenessmodel analysisself‐monitoring blood glucosetype 2 diabetes

Identifiers

PMID41309289
PMCPMC12803682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.